Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.57 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858009 | 0.96 | EPHX2 (0.57) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5608363 | 0.88 | EPHX2 (0.50) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4889654 | 0.87 | EPHX2 (0.49) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4879234 | 0.85 | EPHX2 (0.48) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23246133 | 0.85 | EPHX2 (0.67) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21461246 | 0.85 | EPHX2 (0.62) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21461245 | 0.85 | EPHX2 (0.62) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21461244 | 0.85 | EPHX2 (0.62) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15228444 | 0.85 | EPHX2 (0.62) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23246134 | 0.85 | EPHX2 (0.67) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279170-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | claimed |
| CN-107430355-B | Coating liquid for coating resist pattern and pattern forming method | 日产化学工业株式会社 | 2023-07-14 | — | — | CN | claimed |
| CN-111909041-B | Preparation method of medicine for treating neurological diseases | 山东罗欣药业集团恒欣药业有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-112341340-B | Green and efficient preparation method of medicine for treating Alzheimer's disease | 山东罗欣药业集团恒欣药业有限公司 | 2023-02-17 | — | — | CN | claimed |
| CN-115073304-A | Post-treatment preparation method of memantine hydrochloride | 北京云鹏鹏程医药科技有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-113387815-A | Green preparation method of memantine | 刘振洋 | 2021-09-14 | — | — | CN | claimed |
| CN-112341340-A | Green and efficient preparation method of medicine for treating Alzheimer's disease | 山东罗欣药业集团恒欣药业有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-111909041-A | Preparation method of medicine for treating neurological diseases | 山东罗欣药业集团恒欣药业有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-110845339-A | Synthetic method of memantine hydrochloride | 湖南洞庭药业股份有限公司 | 2020-02-28 | — | — | CN | claimed |
| EP-2882291-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | ZCL CHEMICALS LTD (IN) | 2017-09-27 | — | — | EP | claimed |
| WO-2009057140-A2 | IMPROVED PROCESS FOR MEMANTINE HYDROCHLORIDE | MSN LABORATORIES LIMITED (IN) | 2009-05-07 | — | — | WO | claimed |
| EP-1999100-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-12-10 | — | — | EP | claimed |
| US-7405324-B2 | Process for synthesising aminoadamantanes | A.M.S.A. ANONIMA MATERIE SINTETICHE E. AFINI S.P.A. (IT) | 2008-07-29 | — | — | US | claimed |
| WO-2008062472-A2 | PROCESS FOR THE PREPARATION OF MEMANTINE | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | claimed |
| WO-2008040560-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE AND ITS HYDROCHLORIC ACID SALT FORM | KRKA, D.D., NOVO MESTO (SI) | 2008-04-10 | — | — | WO | claimed |
| EP-1908748-A1 | Process for the preparation of memantine and its hydrochloric acid salt form | KRKA (SI) | 2008-04-09 | — | — | EP | claimed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-20060258885-A1 | chemical preparing acetamido adamantanes intermediate first from halogen adamantane, use for making N-methyl-D-aspartic acid (NDMA) receptor antagonist, treating Parkinson's Disease, central nervous system disorders | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A. | 2006-11-16 | — | — | US | claimed |
| EP-1721888-A1 | Process for synthesising aminoadamantanes | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. (IT) | 2006-11-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258885-A1 | chemical preparing acetamido adamantanes intermediate first from halogen adamantane, use for making N-methyl-D-aspartic acid (NDMA) receptor antagonist, treating Parkinson's Disease, central nervous system disorders | CHRM1, CHRNA5, GRIN2A | EPHX2 3790/4885GRIN2D 26/4885GRIN3B 69/4885 |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | PNMT, PSEN2, CHRNA5 | EPHX2 2141/4885GRIN2D 68/4885GRIN3B 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.